PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsAdenosine phosphate
Adenosine phosphate
Adenosine (adenosine phosphate) is a small molecule pharmaceutical. Adenosine phosphate was first approved as Adenocard on 1989-10-30. It is known to target transient receptor potential cation channel subfamily M member 4.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
Code
Description
J0153
Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds)
Clinical
Clinical Trials
453 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C50334924112105
LeukemiaD007938—C95355471178
Precursor cell lymphoblastic leukemia-lymphomaD054198—C91.0223741—54
Coronary artery diseaseD003324—I25.13141513
AsthmaD001249EFO_0000270J451311410
Myocardial ischemiaD017202EFO_1001375I20-I25112137
Coronary diseaseD003327——112115
Insulin resistanceD007333EFO_0002614E88.8191112—4
InflammationD007249MP_0001845——1—214
Kidney diseasesD007674EFO_0003086N08——1113
Show 15 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myeloid leukemia acuteD015470—C92.030607—185
Myelodysplastic syndromesD009190—D4626424——58
NeoplasmsD009369—C8020131—129
Myeloid leukemiaD007951—C9210183—127
LymphomaD008223—C85.910171——21
Myelomonocytic leukemia chronicD015477—C93.1591——13
PreleukemiaD011289——891——12
Lymphoid leukemiaD007945—C91392——12
Congenital abnormalitiesD000013EFO_0003915Q89.9471——10
Myelomonocytic leukemia acuteD015479—C92.5441——8
Show 42 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Non-hodgkin lymphomaD008228—C85.91117———23
Hematologic neoplasmsD019337——108——117
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_0000340—511———15
Multiple myelomaD009101—C90.0510———13
Hodgkin diseaseD006689—C8189———13
RecurrenceD012008——58———13
B-cell chronic lymphocytic leukemiaD015451—C91.187———12
Neoplasm metastasisD009362EFO_0009708—65——211
Non-small-cell lung carcinomaD002289——45———8
Biphenotypic leukemia acuteD015456—C95.045———8
Show 128 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Obsessive-compulsive disorderD009771EFO_0004242F421———23
Chronic coughD000096822—R05.31———12
Magnetic resonance imagingD008279——1———12
Castration-resistant prostatic neoplasmsD064129——1————1
Leukemia myeloid chronic atypical bcr-abl negativeD054438—C92.21————1
ThrombocytosisD013922—D75.831————1
Lymphoproliferative disordersD008232Orphanet_2442D47.91————1
NeutropeniaD009503—D701————1
Bone marrow diseasesD001855——1————1
Bone marrow transplantationD016026——1————1
Show 15 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Heart diseasesD006331EFO_0003777I51.9————44
Diabetes mellitusD003920EFO_0000400E08-E13————33
ObesityD009765EFO_0001073E66.9————33
Type 2 diabetes mellitusD003924EFO_0001360E11————22
PregnancyD011247EFO_0002950Z33.1————22
Chronic kidney failureD007676EFO_0003884N18.6————22
Craniofacial abnormalitiesD019465——————22
ArthrogryposisD001176EFO_0003857Q74.3————22
Post-traumatic stress disordersD013313EFO_0001358F43.1————22
Feeding and eating disordersD001068—F50————22
Show 70 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameAdenosine phosphate
INNadenosine phosphate
Description
Adenosine 5'-monophosphate is a purine ribonucleoside 5'-monophosphate having adenine as the nucleobase. It has a role as an EC 3.1.3.11 (fructose-bisphosphatase) inhibitor, an EC 3.1.3.1 (alkaline phosphatase) inhibitor, an adenosine A1 receptor agonist, a nutraceutical, a micronutrient, a fundamental metabolite and a cofactor. It is an adenosine 5'-phosphate and a purine ribonucleoside 5'-monophosphate. It is a conjugate base of an adenosine 5'-monophosphate(1+). It is a conjugate acid of an adenosine 5'-monophosphate(2-).
Classification
Small molecule
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]1O
Identifiers
PDB—
CAS-ID61-19-8
RxCUI—
ChEMBL IDCHEMBL752
ChEBI ID16027
PubChem CID6083
DrugBankDB00131
UNII ID415SHH325A (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 68,487 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
1,412 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use